Single-domain antibodies for targeting, detection and in vivo imaging of human CD4+ cells
B. Traenkle, P. D. Kaiser, S. Pezzana, J. Richardson, M. Gramlich, T. R. Wagner, D. Seyfried, M. Weldle, S. Holz, Y. Parfyonova, M. Schaller, S. Nueske, A. Scholz, A. Zeck, M. Jakobi, N. Schneiderhan-Marra, A. Maurer, C. Gouttefangeas, M. Kneilling, B. J. Pichler, D. Sonanini, U. Rothbauer
Abstract
The advancement of new immunotherapies necessitates appropriate probes to monitor the presence and distribution of distinct immune cell populations. Considering the key role of CD4+ T cells in regulating immunological processes, we generated novel single-domain antibodies (nanobodies, Nbs) that specifically recognize human CD4. After in depth analysis of their binding properties, recognized epitopes, and effects on T cell proliferation, activation and cytokine release, we selected CD4 Nbs that did not interfere with crucial T cell processes in vitro and converted them into immune tracers for non-invasive molecular imaging. By optical imaging, we demonstrate the ability of a high-affinity CD4-Nb to specifically visualize CD4+ cells in vivo using a xenograft model. Furthermore, time-resolved immune positron emission tomography (immunoPET) of a human CD4 knock-in mouse model showed rapid accumulation of 64Cu-radiolabeled CD4-Nb in CD4+ T cell-rich tissues. We propose that the CD4 Nbs presented here could serve as versatile probes for stratifying patients and monitoring individual immune responses during personalized immunotherapy in both cancer and inflammatory diseases.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Making the effect visible - OX40 targeting nanobodies for in vivo imaging of activated T cells
Desiree Isabella Frecot, Simone Blaess, … Ulrich Rothbauer·Frontiers in ImmunologyPeer-reviewed·Oct 15, 2024
- Single-domain antibodies targeting the pan-T-cell markers CD2 and CD7 as universal immunotherapy T-cell tracers
Dario Gosmann, Lisa Russelli, … Angela M. Krackhardt·bioRxiv·Dec 25, 2025
- Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells
T. R. Wagner, S. Blaess, … U. Rothbauer·bioRxiv·Jun 27, 2023
- In vivo imaging of T-cell coregulator B7-H4 reveals protumor macrophage status in prostate cancer
Manoj Kumar, Shashi Bhushan Singh, … Heike Elisabeth Daldrup-Link·bioRxiv·Sep 28, 2024
- The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions
J. C. Osorio, P. Smith, … J. Ravetch·bioRxiv·Jun 29, 2023
- A CTLA-4 nanobody improves the immunity of mice against challenges with Staphylococcus aureus and Streptococcus agalactiae
P. Wu, N. n. Yang, … c. chen·bioRxiv·Mar 5, 2021